Press releases

Press release
Medivir appoints Dr. Linda Basse as Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Linda Basse as Chief Medical Officer effective October...

Read more
Press release
Investigator-initiated phase II clinical study of remetinostat started in patients with basal cell carcinoma

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient has been enrolled and is being dosed...

Read more
Press release
MIV-711 osteoarthritis phase IIa extension study outcomes show continuing positive effect on joint structure

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces positive top-line joint structure outcomes from the MIV-711 osteoarthritis phase IIa...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2018

April – JuneSignificant events during the quarter Positive top-line results from the MIV-711 osteoarthritis phase IIa extension study. The study met...

Read more
Press release
Medivir announces positive top-line results from the MIV-711 osteoarthritis phase IIa extension study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced positive top-line results from the MIV-711 phase IIa extension study (MIV-711-202)....

Read more
Press release
Continued discussions with FDA on proposed remetinostat phase III design results in delay in planned start of study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Board of Directors have decided to continue the discussions...

Read more
Press release
Phase I/II study design of birinapant in combination with Keytruda® to be presented on June 4 at the ASCO Annual Meeting

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that the design of the ongoing phase I/II study of birinapant...

Read more
Press release
Additional remetinostat phase II data will be presented at the International Investigative Dermatology meeting on May 18 and 19

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that additional data from the phase II study of remetinostat in...

Read more
Press release
Resolutions at the Annual General Meeting in Medivir on 3 May 2018

Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing directorThe...

Read more
Press release
Number of shares and votes in Medivir

Stockholm, Sweden - Medivir AB (”Medivir” or the ”Company”) (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2018

Significant events during the quarter The holders of series A shares have notified the Company that they will convert all their...

Read more
Press release
Data from the MIV-711 initial phase IIa study will be presented at the OARSI World Congress on April 27

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that data from the initial phase IIa study of MIV-711, which...

Read more